logo
Plus   Neg
Share
Email

AstraZeneca Announces Fast Track Designation For FARXIGA - Quick Facts

AstraZeneca (AZN.L,AZN) said the US FDA has granted Fast Track designation for the development of FARXIGA to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction or preserved ejection fraction. The designation is based on two Phase III trials, DAPA-HF and DELIVER.

FARXIGA is currently approved as a monotherapy and as part of combination therapy to improve glycemic control in adults with type 2 diabetes. In August, FARXIGA was granted Fast Track designation for the development to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
Follow RTT